Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

cMET Exon 14 Skipping: From the Structure to the Clinic.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2016

Van Der Steen Nele, Giovannetti Elisa, Pauwels Patrick, Peters Godefridus J, Hong David S, Cappuzzo Federico, Hirsch Fred R, Rolfo Christian

Abstract excerpt

The abnormal stimulation of the multiple signal transduction pathways downstream of the receptor tyrosine kinase mesenchymal-epithelial transition factor (cMET) promotes cellular transformation, tumor motility, and invasion. Therefore, cMET has been the focus of prognostic and therapeutic studies in different tumor types, including non-small cell lung cancer. In particular, several cMET inhibitors have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exons
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins c-met

Share to RNA Splicing

Share to Signal Transduction

Source

Identifiers

PMID: 27223456
DOI: 10.1016/j.jtho.2016.05.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

cMET Exon 14 Skipping: From the Structure to the Clinic.PMID 27223456Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Semantic proximity Read ↗

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.Semantic proximity Read ↗

New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.